Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Alone After Stem-Cell Transplant for Multiple Myeloma

Inclusion Criteria

• Completed a single autologous stem cell transplant after no more than two induction treatments (excluding dexamethasone alone) and have stable disease within 100 days post-transplant.
• Started induction therapy within the last 12 months and had no more than two prior induction treatments.
• Provide a bone marrow sample at the start of the study for MRD evaluation.
• Be 18 years or older.
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Have adequate liver function and specific blood counts within normal limits.
• Have good kidney function.
• Women of childbearing potential must have two negative pregnancy tests before starting Lenalidomide and agree to use two forms of birth control or abstain from sex during the study and for 28 days after.
• Men must agree to use a condom during sex with women of childbearing potential while in the study and for 28 days after.
• Agree to participate in the Revlimid REMS® program and follow its requirements.
• Provide written informed consent to participate in the study.

Exclusion Criteria

• Have had more than 12 months of prior therapy, unless considered on a case-by-case basis.
• Experienced disease progression after initial therapy.
• Have already started or received post-transplant maintenance or consolidation treatment.
• Cannot tolerate Lenalidomide, Carfilzomib, or Dexamethasone.
• Have certain other medical conditions, such as POEMS syndrome, plasma cell leukemia, or Waldenström's macroglobulinemia.
• Have significant nerve damage or severe diarrhea.
• Have cancer that has spread to the brain or spinal cord.
• Are pregnant or breastfeeding.
• Have had recent radiotherapy or major surgery.
• Have had a heart attack or severe heart problems recently.
• Have a history of blood clots or uncontrolled high blood pressure or diabetes.
• Have an active infection or are HIV, hepatitis B, or hepatitis C positive.
• Have had another type of cancer in the past three years, except for certain skin or prostate cancers.
• Have any other medical condition that might interfere with the study or the ability to give informed consent.